Franz Von Nussbaum

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Strategic Key Performance Indicators for AI in Lead Optimization.

Strategic Key Performance Indicators for AI in Lead Optimization.

Journal: ChemMedChem

Published: November 28, 2025

Opening the Door to a New Treatment Paradigm: The Re-emergence of Chymase Inhibitors.

Opening the Door to a New Treatment Paradigm: The Re-emergence of Chymase Inhibitors.

Journal: Journal of medicinal chemistry

Published: February 17, 2025

Identification of NUV-244 as a PNPLA3 I148M degrading small molecule.

Identification of NUV-244 as a PNPLA3 I148M degrading small molecule.

Journal: iScience

Published: September 03, 2024

Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.

Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.

Journal: Cell chemical biology

Published: September 18, 2023

European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe.

European Medicinal Chemistry Leaders in Industry (EMCL) - On the Status and Future of Medicinal Chemistry Research in Europe.

Journal: ChemMedChem

Published: March 02, 2023

Frontiers in Medicinal Chemistry 2022 Goes Virtual.

Frontiers in Medicinal Chemistry 2022 Goes Virtual.

Journal: ChemMedChem

Published: July 30, 2022

Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.

Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.

Journal: Journal of medicinal chemistry

Published: October 26, 2021

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.

Journal: Journal of medicinal chemistry

Published: July 15, 2021

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.

The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: December 16, 2020

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

Journal: Journal of medicinal chemistry

Published: June 06, 2020

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Journal: Journal of medicinal chemistry

Published: April 28, 2020

Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.

Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.

Journal: Journal of medicinal chemistry

Published: December 21, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026